Medbox, Inc. Announces Creation of a Shareholder Due Diligence Q&A Section on the Company's Website

Apr 16, 2014, 09:00 ET from Medbox, Inc.

LOS ANGELES, Apr. 16, 2014 /PRNewswire/ -- Medbox, Inc. (OTCQB: MDBX) (, a leader in providing ancillary services to the alternative medicine industry, dispensary consulting services, and patented medicine dispensing systems to medical and retail industries, today announced creation of a shareholder due diligence and Q&A page on the company's website.

The purpose of the web content is to help answer questions received from shareholders, potential shareholders and investigative journalists in an outwardly transparent manner.

"The point is setting the standard for all companies to follow in our industry," stated Vincent Mehdizadeh, Senior Strategist and Founder at Medbox. "The high profile that the industry and market has awarded us makes us a target for overzealous and sometimes unscrupulous 'Short Journalists' that will ask questions, distort company responses, and publish content that is misleading and factually inaccurate. This strategy will enable Medbox to document questions that are presented to us and that we feel warrant a response. That is the level of transparency the investment community deserves."

In addition, recently, a few public companies in the marijuana industry had trading suspended by the SEC due to a lack of "adequacy and accuracy of information" about their companies.

"We are a new SEC filer and strive to bring legitimacy to this new industry as it is taking shape," stated Dr. Bruce Bedrick CEO of Medbox. "As a company, we take pride in the steps we have taken to get here and the steps we will ultimately take to reach our next goals of capturing additional revenue, maintaining shareholder value through our dynamic and disruptive technologies, and also thinking outside the box as to shareholder communications. We have a great rapport with our shareholders and it is an honor serving them and building our brand."

The Due Diligence Q&A can be found on the company's website by clicking here or by visiting the company's website and clicking on the Investor DD tab on the top navigation menu. The section may be updated quarterly with additional questions and answers at the company's discretion. Interested parties may submit questions to for further handling and consideration.

About Medbox, Inc: 

Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Headquartered in Los Angeles, Medbox, through its wholly owned subsidiary, Medicine Dispensing Systems, offers their patented systems, software and consulting services to pharmacies, alternative medicine dispensaries and local governments in the U.S. In addition, through its wholly owned subsidiary, Vaporfection International, Inc. (, the company offers an industry award winning medical vaporizer product. Medbox, through its newly established subsidiaries, also engages in the following ancillary services catered to the alternative medicine industry: merchant services and armored transport for cash deposits, cannabidiol R&D, real estate acquisitions and subsequent lease programs to alternative medicine dispensaries, and also alternative medicine dispensary management services.

Medbox, Inc. is a publicly traded company, and is quoted on the OTCQB, ticker symbol MDBX.

Forward-Looking Statements: The statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties include, but are not limited to, technical advances in the industry as well as political and economic conditions present within the industry. We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made. 

For more information on Medbox, please contact the company at (800) 762-1452 or go online to

For additional due diligence information, visit


Investor Relations
Stephen Hart 
Hayden IR 
+1- 917-658-7878 

SOURCE Medbox, Inc.